DRL sells brand Sernivo; grants Promiseb and Trianex US marketing rights to Encore Dermatology

Dr. Reddy’s Laboratories Limited through its wholly owned subsidiary Promius Pharma, LLC, announces the sale of its rights for Sernivo (betamethasone dipropionate) spray, 0.05% and assignment of its rights to market and distribute, Promiseb topical cream and Trianex 0.05% (triamcinolone acetonide ointment, USP) in the United States, to Encore Dermatology.

Under the terms of the agreement, Promius Pharma is eligible to receive an upfront payment and future milestone payments contingent upon achievement of certain commercial objectives. Dr. Reddy’s Laboratories Ltd. an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Promius Pharma is a wholly-owned subsidiary of Dr. Reddy’s Laboratories, one of the largest and most respected pharmaceutical companies in the world.

Headquartered in Malvern, Pennsylvania, Encore Dermatology, Inc. is a privately held fully-integrated dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients.